MyMedR

Displaying all 4 publications

Abstract:

Sort:

Enhancing urban blue-green landscape quality assessment through hybrid genetic algorithm-back propagation (GA-BP) neural network approach: a case study in Fucheng, China

Fan D, Maliki NZB, Yu S, Jin F, Han X

Environ Monit Assess, 2024 Apr 04;196(5):424.
PMID: 38573531 DOI: 10.1007/s10661-024-12558-6

This study employs an artificial neural network optimization algorithm, enhanced with a Genetic Algorithm-Back Propagation (GA-BP) network, to assess the service quality of urban water bodies and green spaces, aiming to promote healthy urban environments. From an initial set of 95 variables, 29 key variables were selected, including 17 input variables, such as water and green space area, population size, and urbanization rate, six hidden layer neurons, such as patch number, patch density, and average patch size, and one output variable for the comprehensive value of blue-green landscape quality. The results indicate that the GA-BP network achieves an average relative error of 0.94772%, which is superior to the 1.5988% of the traditional BP network. Moreover, it boasts a prediction accuracy of 90% for the comprehensive value of landscape quality from 2015 to 2022, significantly outperforming the BP network's approximate 70% accuracy. This method enhances the accuracy of landscape quality assessment but also aids in identifying crucial factors influencing quality. It provides scientific and objective guidance for future urban landscape structure and layout, contributing to high-quality urban development and the creation of exemplary living areas.
Long-term impact of biochar on the immobilisation of nickel (II) and zinc (II) and the revegetation of a contaminated site

Shen Z, Som AM, Wang F, Jin F, McMillan O, Al-Tabbaa A

Sci Total Environ, 2016 Jan 15;542(Pt A):771-6.
PMID: 26551277 DOI: 10.1016/j.scitotenv.2015.10.057

A field remediation treatment was carried out to examine the long-term effect of biochar on the immobilisation of metals and the revegetation of a contaminated site in Castleford, UK. The extracted concentrations of nickel (Ni) (II) and zinc (Zn) (II) in the carbonic acid leaching tests were reduced by 83-98% over three years. The extracted Ni (II) and Zn (II) concentrations three years after the treatment were comparable to a cement-based treatment study carried out in a parallel manner on the same site. The sequential extraction results indicated that biochar addition (0.5-2%) increased the residue fractions of Ni (II) (from 51% to 61-66%) and Zn (II) (from 7% to 27-35%) in the soils through competitive sorption, which may have resulted in the reduction of leachabilities of Ni (II) (from 0.35% to 0.12-0.15%) and Zn (II) (from 0.12% to 0.01%) in the plots with biochar compared with that without biochar three years after the treatment. The germination of grass in the plots on site failed. Further laboratory pot study suggested that larger amounts of biochar (5% or more) and compost (5% or more) were needed for the success of revegetation on this site. This study suggests the effectiveness and potential of biochar application in immobilising heavy metals in contaminated site in the long term.
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G, et al.

Lancet, 2019 11 23;394(10212):1915-1928.
PMID: 31679945 DOI: 10.1016/S0140-6736(19)32591-7

BACKGROUND: Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC), with programmed cell death ligand 1 (PD-L1) expression associated with improved response.
METHODS: KEYNOTE-048 was a randomised, phase 3 study of participants with untreated locally incurable recurrent or metastatic HNSCC done at 200 sites in 37 countries. Participants were stratified by PD-L1 expression, p16 status, and performance status and randomly allocated (1:1:1) to pembrolizumab alone, pembrolizumab plus a platinum and 5-fluorouracil (pembrolizumab with chemotherapy), or cetuximab plus a platinum and 5-fluorouracil (cetuximab with chemotherapy). Investigators and participants were aware of treatment assignment. Investigators, participants, and representatives of the sponsor were masked to the PD-L1 combined positive score (CPS) results; PD-L1 positivity was not required for study entry. The primary endpoints were overall survival (time from randomisation to death from any cause) and progression-free survival (time from randomisation to radiographically confirmed disease progression or death from any cause, whichever came first) in the intention-to-treat population (all participants randomly allocated to a treatment group). There were 14 primary hypotheses: superiority of pembrolizumab alone and of pembrolizumab with chemotherapy versus cetuximab with chemotherapy for overall survival and progression-free survival in the PD-L1 CPS of 20 or more, CPS of 1 or more, and total populations and non-inferiority (non-inferiority margin: 1·2) of pembrolizumab alone and pembrolizumab with chemotherapy versus cetuximab with chemotherapy for overall survival in the total population. The definitive findings for each hypothesis were obtained when statistical testing was completed for that hypothesis; this occurred at the second interim analysis for 11 hypotheses and at final analysis for three hypotheses. Safety was assessed in the as-treated population (all participants who received at least one dose of allocated treatment). This study is registered at ClinicalTrials.gov, number NCT02358031.
FINDINGS: Between April 20, 2015, and Jan 17, 2017, 882 participants were allocated to receive pembrolizumab alone (n=301), pembrolizumab with chemotherapy (n=281), or cetuximab with chemotherapy (n=300); of these, 754 (85%) had CPS of 1 or more and 381 (43%) had CPS of 20 or more. At the second interim analysis, pembrolizumab alone improved overall survival versus cetuximab with chemotherapy in the CPS of 20 or more population (median 14·9 months vs 10·7 months, hazard ratio [HR] 0·61 [95% CI 0·45-0·83], p=0·0007) and CPS of 1 or more population (12·3 vs 10·3, 0·78 [0·64-0·96], p=0·0086) and was non-inferior in the total population (11·6 vs 10·7, 0·85 [0·71-1·03]). Pembrolizumab with chemotherapy improved overall survival versus cetuximab with chemotherapy in the total population (13·0 months vs 10·7 months, HR 0·77 [95% CI 0·63-0·93], p=0·0034) at the second interim analysis and in the CPS of 20 or more population (14·7 vs 11·0, 0·60 [0·45-0·82], p=0·0004) and CPS of 1 or more population (13·6 vs 10·4, 0·65 [0·53-0·80], p<0·0001) at final analysis. Neither pembrolizumab alone nor pembrolizumab with chemotherapy improved progression-free survival at the second interim analysis. At final analysis, grade 3 or worse all-cause adverse events occurred in 164 (55%) of 300 treated participants in the pembrolizumab alone group, 235 (85%) of 276 in the pembrolizumab with chemotherapy group, and 239 (83%) of 287 in the cetuximab with chemotherapy group. Adverse events led to death in 25 (8%) participants in the pembrolizumab alone group, 32 (12%) in the pembrolizumab with chemotherapy group, and 28 (10%) in the cetuximab with chemotherapy group.
INTERPRETATION: Based on the observed efficacy and safety, pembrolizumab plus platinum and 5-fluorouracil is an appropriate first-line treatment for recurrent or metastatic HNSCC and pembrolizumab monotherapy is an appropriate first-line treatment for PD-L1-positive recurrent or metastatic HNSCC.
FUNDING: Merck Sharp & Dohme.
Fulltext Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, Abdellatif M, Abdoli A, Abel S, et al.

Autophagy, 2021 Jan;17(1):1-382.
PMID: 33634751 DOI: 10.1080/15548627.2020.1797280

In 2008, we published the first set of guidelines for standardizing research in autophagy. Since then, this topic has received increasing attention, and many scientists have entered the field. Our knowledge base and relevant new technologies have also been expanding. Thus, it is important to formulate on a regular basis updated guidelines for monitoring autophagy in different organisms. Despite numerous reviews, there continues to be confusion regarding acceptable methods to evaluate autophagy, especially in multicellular eukaryotes. Here, we present a set of guidelines for investigators to select and interpret methods to examine autophagy and related processes, and for reviewers to provide realistic and reasonable critiques of reports that are focused on these processes. These guidelines are not meant to be a dogmatic set of rules, because the appropriateness of any assay largely depends on the question being asked and the system being used. Moreover, no individual assay is perfect for every situation, calling for the use of multiple techniques to properly monitor autophagy in each experimental setting. Finally, several core components of the autophagy machinery have been implicated in distinct autophagic processes (canonical and noncanonical autophagy), implying that genetic approaches to block autophagy should rely on targeting two or more autophagy-related genes that ideally participate in distinct steps of the pathway. Along similar lines, because multiple proteins involved in autophagy also regulate other cellular pathways including apoptosis, not all of them can be used as a specific marker for bona fide autophagic responses. Here, we critically discuss current methods of assessing autophagy and the information they can, or cannot, provide. Our ultimate goal is to encourage intellectual and technical innovation in the field.